Fulgent Genetics Debt to Equity Ratio 2015-2023 | FLGT
Current and historical debt to equity ratio values for Fulgent Genetics (FLGT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Fulgent Genetics debt/equity for the three months ending December 31, 2023 was 0.00.
| Fulgent Genetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2023-12-31 | $0.10B | $1.13B | 0.09 |
| 2023-09-30 | $0.10B | $1.26B | 0.08 |
| 2023-06-30 | $0.09B | $1.26B | 0.07 |
| 2023-03-31 | $0.11B | $1.27B | 0.09 |
| 2022-12-31 | $0.12B | $1.27B | 0.09 |
| 2022-09-30 | $0.12B | $1.28B | 0.10 |
| 2022-06-30 | $0.15B | $1.31B | 0.12 |
| 2022-03-31 | $0.15B | $1.31B | 0.12 |
| 2021-12-31 | $0.11B | $1.17B | 0.10 |
| 2021-09-30 | $0.16B | $1.04B | 0.15 |
| 2021-06-30 | $0.13B | $0.92B | 0.14 |
| 2021-03-31 | $0.20B | $0.80B | 0.25 |
| 2020-12-31 | $0.13B | $0.57B | 0.23 |
| 2020-09-30 | $0.06B | $0.19B | 0.32 |
| 2020-06-30 | $0.01B | $0.09B | 0.10 |
| 2020-03-31 | $0.01B | $0.08B | 0.10 |
| 2019-12-31 | $0.01B | $0.08B | 0.07 |
| 2019-09-30 | $0.01B | $0.06B | 0.12 |
| 2019-06-30 | $0.01B | $0.05B | 0.10 |
| 2019-03-31 | $0.01B | $0.05B | 0.11 |
| 2018-12-31 | $0.00B | $0.05B | 0.05 |
| 2018-09-30 | $0.00B | $0.05B | 0.04 |
| 2018-06-30 | $0.00B | $0.05B | 0.06 |
| 2018-03-31 | $0.00B | $0.05B | 0.05 |
| 2017-12-31 | $0.00B | $0.05B | 0.06 |
| 2017-09-30 | $0.00B | $0.06B | 0.06 |
| 2017-06-30 | $0.00B | $0.06B | 0.06 |
| 2017-03-31 | $0.00B | $0.06B | 0.06 |
| 2016-12-31 | $0.00B | $0.05B | 0.07 |
| 2016-09-30 | $0.01B | $0.02B | 0.32 |
| 2016-06-30 | $0.01B | $0.02B | 0.23 |
| 2016-03-31 | $0.00B | $0.00B | 0.00 |
| 2015-12-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | $0.00B | 0.26 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.620B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GE HealthCare Technologies (GEHC) | United States | $39.189B | 21.80 |
| Inspire Medical Systems (INSP) | United States | $6.715B | 0.00 |
| 10x Genomics (TXG) | United States | $3.670B | 0.00 |
| Axonics (AXNX) | United States | $3.435B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $3.419B | 0.00 |
| Enovis (ENOV) | United States | $3.098B | 23.54 |
| Azenta (AZTA) | United States | $2.910B | 237.18 |
| Olink Holding AB (publ) (OLK) | Sweden | $2.818B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $2.719B | 0.00 |
| Privia Health (PRVA) | United States | $2.099B | 93.11 |
| Schrodinger (SDGR) | United States | $1.790B | 0.00 |
| Phreesia (PHR) | United States | $1.297B | 0.00 |
| Omnicell (OMCL) | United States | $1.224B | 29.94 |
| Definitive Healthcare (DH) | United States | $0.861B | 0.00 |
| Standard BioTools (LAB) | United States | $0.786B | 0.00 |
| Talkspace (TALK) | United States | $0.512B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.325B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.324B | 0.00 |
| Clover Health Investments (CLOV) | United States | $0.310B | 0.00 |
| Pulmonx (LUNG) | United States | $0.286B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.187B | 0.00 |
| Augmedix (AUGX) | United States | $0.168B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.149B | 0.00 |
| American Well (AMWL) | United States | $0.149B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.129B | 0.00 |
| TruBridge (TBRG) | United States | $0.122B | 5.22 |
| Outset Medical (OM) | United States | $0.108B | 0.00 |
| 111 (YI) | China | $0.084B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.076B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.074B | 0.00 |
| Zepp Health (ZEPP) | China | $0.052B | 0.00 |
| HeartBeam (BEAT) | United States | $0.047B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.045B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.034B | 0.00 |
| Movano (MOVE) | United States | $0.026B | 0.00 |
| Cue Health (HLTH) | United States | $0.023B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.019B | 0.00 |
| ETAO (ETAO) | United States | $0.019B | 0.00 |
| CareCloud (CCLD) | United States | $0.019B | 0.00 |
| Akili (AKLI) | United States | $0.018B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.017B | 0.00 |
| Centogene (CNTG) | Germany | $0.013B | 0.00 |
| Biotricity (BTCY) | United States | $0.011B | 0.00 |
| Transgenomic (PRPO) | United States | $0.010B | 0.00 |
| Syra Health (SYRA) | United States | $0.007B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.006B | 0.00 |
| Zhongchao (ZCMD) | China | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |